Table 3

Association between exposure to inhaled corticosteroids and cataract: adjusted models and dose-response relation

Univariate analysisAdjusting for systemic steroidsAdjusting for systemic steroids and consultation rate
Cases (n = 15479)Controls (n = 15479)Odds ratio (95% CI)Odds ratio (95% CI)Odds ratio (95% CI)p Value
*p Value for trend.
Inhaled corticosteroids:
Never13713 (88.6%)14299 (92.4%)BaselineBaselineBaseline
Ever1766 (11.4%)1180 (7.6%)1.58 (1.46 to 1.71)1.32 (1.21 to 1.44)1.10 (1.00 to 1.20)0.049
Current1319 (8.5)829 (5.4)1.67 (1.53 to 1.83)1.39 (1.26 to 1.53)1.15 (1.03 to 1.27)0.01
Past only447 (2.9)351 (2.3)1.35 (1.17 to 1.56)1.16 (1.00 to 1.35)0.98 (0.84 to 1.14)0.8
Daily dose:
None13713 (88.6%)14299 (92.4%)BaselineBaselineBaseline
Low (up to 400 μg)637 (4.1%)496 (3.2%)1.36 (1.20 to 1.53)1.18 (1.05 to 1.34)0.99 (0.87 to 1.13)0.002*
Moderate (401–800 μg)430 (2.8%)264 (1.7%)1.73 (1.48 to 2.02)1.45 (1.24 to 1.71)1.18 (1.00 to 1.39)
High (801–1600 μg)382 (2.5%)221 (1.4%)1.82 (1.54 to 2.15)1.46 (1.23 to 1.74)1.18 (0.99 to 1.42)
Very high (>1600 μg)117 (0.8%)43 (0.3%)2.87 (2.02 to 4.08)2.21 (1.55 to 3.16)1.69 (1.17 to 2.43)
Missing data200 (1.3%)156 (1.0%)
Number of prescriptions:
No13713 (88.6%14299 (92.4%)BaselineBaselineBaseline
1–9793 (5.1%)589 (3.8%)1.41 (1.27 to 1.58)1.23 (1.09 to 1.37)1.03 (0.91 to 1.16)0.004*
10–19373 (2.4%)246 (1.6%)1.60 (1.36 to 1.89)1.33 (1.12 to 1.57)1.07 (0.90 to 1.27)
20–29210 (1.4%)122 (0.8%)1.84 (1.46 to 2.30)1.50 (1.19 to 1.90)1.22 (0.96 to 1.55)
30–39148 (1.0%)88 (0.6%)1.76 (1.35 to 2.30)1.44 (1.10 to 1.89)1.23 (0.93 to 1.62)
⩾40242 (1.6%)135 (0.9%)1.92 (1.55 to 2.39)1.55 (1.24 to 1.93)1.28 (1.01 to 1.61)